MINIMAL RESIDUAL DISEASE
Clinical trials for MINIMAL RESIDUAL DISEASE explained in plain language.
Never miss a new study
Get alerted when new MINIMAL RESIDUAL DISEASE trials appear
Sign up with your email to follow new studies for MINIMAL RESIDUAL DISEASE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New immunotherapy mops up leftover leukemia cells
Disease control CompletedThis study tested a drug called blinatumomab in 36 adults with B-cell acute lymphoblastic leukemia whose cancer was in remission but still had a few hidden cancer cells (minimal residual disease). The drug helps the immune system attack and destroy those leftover cells. The goal …
Matched conditions: MINIMAL RESIDUAL DISEASE
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 05:06 UTC
-
New immunotherapy targets Hard-to-Treat cancers in early trial
Disease control CompletedThis early-phase trial tested a new immunotherapy called ELI-002 in 25 people with KRAS-mutated pancreatic, colorectal, lung, ovarian, or bile duct cancers that had minimal residual disease after standard treatment. The goal was to see if the treatment is safe and can reduce canc…
Matched conditions: MINIMAL RESIDUAL DISEASE
Phase: PHASE1 • Sponsor: Elicio Therapeutics • Aim: Disease control
Last updated May 26, 2026 05:05 UTC
-
New approach uses targeted therapy to control metastatic lung cancer
Disease control CompletedThis study looked at whether a targeted treatment called local ablative therapy (LAT) can help control metastatic non-small cell lung cancer (NSCLC) when a blood test shows rising levels of cancer DNA (minimal residual disease or MRD). 37 participants received LAT to all visible …
Matched conditions: MINIMAL RESIDUAL DISEASE
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 22, 2026 14:03 UTC
-
Immune cells take on tough leukemia in early trial
Disease control CompletedThis early-phase study tested a new therapy made from lab-grown natural killer (NK) cells in 2 adults with acute myeloid leukemia (AML) that had come back or was hard to treat. The goal was to see if the treatment is safe and to get a first look at whether it can reduce signs of …
Matched conditions: MINIMAL RESIDUAL DISEASE
Phase: PHASE1 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated May 15, 2026 11:53 UTC